Photo by vidarnm from unsplash
Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between… Click to show full abstract
Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors, but no detailed research has been conducted. In this retrospective cohort study, we aimed to identify the factors associated with Atomoxetine efficacy.
Keywords:
hyperactivity disorder;
attention deficit;
efficacy;
adult attention;
efficacy atomoxetine;
deficit hyperactivity
Journal Title: Neuropsychopharmacology Reports
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Neuropsychopharmacology Reports
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!